IQWiG says Gilead’s anti-HIV drug genvoya offers slightly lower benefits than competition
April 11, 2016Medical Communications, Research and Development Bristol-Myers Squibb, Gilead, HIV, anti-HIV
German Institute for Quality and Efficiency in Health Care (IQWiG) said USdrug maker Gilead’s (Nasdaq: GILD) anti-HIV drug Genvoya provides marginally …
GW Pharma starts Phase III trials for Tuberous Sclerosis Complex drug
April 11, 2016Research and Development Epidiolex, GW Pharmaceuticals, Tuberous Sclerosis Complex, genetics, rare disease
GW Pharmaceuticals Plc (Nasdaq: GWPH) said it has started late-stage trials for its Epidiolex (cannabidiol or CBD) to treat seizures …
Mylan launches new dosages of generic of Novartis hypertension drug in US
April 11, 2016Manufacturing and Production Mylan, Novartis, generic, high blood pressure, hypertension
Mylan (TASE: MYL) has announced the US launch of new dosages of its generic version of Novartis’s hypertension drug, Lopressor …
Former US CEO of Boehringer Ingelheim becomes chairman at Inotek Pharmaceuticals
April 11, 2016Medical Communications Boehringer Ingelheim, inotek, inotek pharma, j martin carroll
Inotek Pharmaceuticals has announced the appointment of J. Martin Carroll as the new chairman of the board. Carroll will succeed …
Weekly Movers: Array BioPharma, Amicus Therapeutics, Genocea Biosciences, Tesaro Inc, Incyte, Clovis Oncology
April 11, 2016Manufacturing and Production, Research and Development, Sales and Marketing Index, Movers, markets, stocks
Shares in Botox-maker Allergan (NYSE: AGN) plunged over 17% in intra-day trading as the $160 billion merger seal with US …
Depomed criticised by investors and urged to explore potential sale
April 11, 2016Sales and Marketing Depomed, board, horizon, sale, starboard, starboard value
Only a few short months after fighting off a $1 billion bid from Horizon Pharma, investors at Depomed have called …
FDA staff raises doubts on efficacy, safety of Clovis’ trial drug for lung cancer, shares plunge
April 11, 2016AstraZeneca, Clovis Oncology, US FDA, drug trial, lung cancer, regulation, rociletinib
Shares in Clovis Oncology Inc (Nasdaq: CLVS) plunged to close down nearly 18% after the US regulators expressed doubts if …
Roche’s cancer immunotherapy for lung cancer gets US FDA priority review
April 11, 2016Business Services, Research and Development, Sales and Marketing Roche, US FDA, atezolizumab, lung cancer
Swiss drug firm Roche (SIX: ROG) on Monday said the US Food and Drug Administration (FDA) has accepted its Biologics …
Midatech launch treatment to reduce chemo-induced vomiting in the US
April 11, 2016Research and Development, Sales and Marketing chemotherapy, midatech, nausea, oncology, radiation, vomiting
Midatech Pharma (NASDAQ: MTP) has the full commercial launch of Zuplenz (ondansetron) in the US. The drug is an oral …
Sun Pharma receives FDA approval for ocular pain treatment
April 11, 2016Research and Development, Sales and Marketing FDA, Sun Pharma, bromsite, ocular treatment
Sun Pharma (BSE: 524715) has announced that their ocular pain prevention treatment, BromSite (bromfenac ophthalmic solution), has been approved by …
Celgene says disappointed with NICE decision to not back blood cancer drug
April 8, 2016Business Services, Medical Communications, Sales and Marketing
US drugmaker Celgene Corp (Nasdaq: CELG) on Friday said it is disappointed with UK regulators’ decision to not recommend Vidaza …
HIV successfully overcomes CRISPR gene-editing technology
April 8, 2016Research and Development HIV, crispr, failure, setback
Researchers using the CRISPR gene-editing technology have indicated that HIV can defeat efforts to cripple it, but have characterised it …
US panel supports accelerated approval for Intercept’s trial drug for rare liver condition
April 8, 2016Medical Communications, Research and Development, Sales and Marketing Intercept Pharmaceuticals, PDUFA, US FDA, liver disorder, rare disease
Intercept Pharmaceuticals (Nasdaq: ICPT) said a US Food and Drug Administration (FDA) advisory committee has recommended accelerated approval for its …
UK’s genomics and personalised medicine expertise showcased at major international gathering
April 8, 2016Manufacturing and Production, Research and Development 000 genomics project, 100, NHS, UK, expertise, genomics, international gathering, world leader
The UK’s expertise in genomics was showcased at a major international gathering to foster global collaboration in this burgeoning field. …
Pfizer, IBM partner to develop monitoring system for Parkinson’s disease
April 8, 2016Medical Communications, Research and Development Parkinson's disease, Pfizer, collaboration, ibm, research, technology
US pharma giant Pfizer (NYSE: PFE) and International Business Machines Corp (NYSE: IBM) have partnered on a research project focussed on …
AstraZeneca and Eli Lilly to enter Phase III on Alzheimer’s clinical trials
April 8, 2016Medical Communications AZD3293, Alzheimer's, Alzheimers, AstraZeneca, amaranth, clinical trial, lilly, phase III
AstraZeneca and Eli Lilly have announced the continuation of their clinical trial for people with early Alzheimer’s disease into Phase …
FTC launches tool to help mobile health app developers determine applicable regulations
April 8, 2016Medical Communications, Sales and Marketing FDA, FTC, apps, health, health apps, regulation
The US Federal Trade Commission has created a new web-based tool for developers of health-related mobile apps to help them …
Vectura to get $10 million milestone as Hikma files ANDA for generic copy of GSK’s asthma drug
April 8, 2016Medical Communications, Research and Development, Sales and Marketing
Vectura Group (LSE: VEC) on Friday said it is set to receive $10 million in milestone payments from partner Hikma …
Sandoz receives EU approval for subcutaneous injection of Binocrit biosimilar
April 8, 2016Medical Communications, Research and Development Sandoz, binocrit, biosimilar, eu approval
Sandoz has received approval from the European Commission for a type II variation for the addition of a subcutaneous route …
Boehringer Ingelheim’s Giotrif gets Europan regulatory backing in another lung cancer indication
April 7, 2016Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, European Commission, giotrif, lung cancer
German drugmaker Boehringer Ingelheim on Thursday said European regulators have granted marketing rights for its non-small cell lung cancer (NSCLC) …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
